Brain Tumor Treatment Denied by Insurance: How to Appeal

Brain tumors — from glioblastoma multiforme (GBM) to lower-grade gliomas, meningiomas, and brain metastases — demand aggressive, multimodal treatment. Insurance denials in neuro-oncology are particularly damaging because brain tumors often progress quickly and because many of the most effective treatments, including the Optune device, stereotactic radiosurgery (SRS), and temozolomide-based therapy, are among the most commonly contested. If your insurer has denied any of these treatments, you have strong grounds to appeal.

Common Brain Tumor Denial Scenarios

Optune (Tumor Treating Fields)

Optune is an FDA-approved wearable device that delivers alternating electric fields (TTFields) to slow tumor cell division. It is approved for newly diagnosed GBM following surgery and chemoradiation, and for recurrent GBM. The device has demonstrated survival benefit in the EF-14 phase III trial, which showed a significant improvement in overall and progression-free survival when added to maintenance temozolomide.

Despite this evidence, Optune is among the most frequently denied brain tumor treatments. Insurers deny it by:

• Calling it "experimental or investigational" despite FDA PMA approval dating to 2011 (recurrent GBM) and 2015 (newly diagnosed GBM)
• Citing lack of "cost-effectiveness" — a criterion not permitted for coverage decisions under most insurance contracts
• Requiring documentation that the patient completed standard chemoradiation before approving Optune for newly diagnosed GBM maintenance
• Applying formulary criteria that exclude durable medical equipment (DME) at certain tiers

Temozolomide (Temodar)

Temozolomide is standard of care in the Stupp protocol (concurrent with radiation, then monthly maintenance) for newly diagnosed GBM with MGMT promoter methylation. Even for unmethylated tumors, temozolomide plus radiation is commonly recommended. Denials of temozolomide are less common than Optune but can occur due to:

• Formulary restrictions on the oral formulation
• Quantity limits on maintenance cycles
• Denial of temozolomide in recurrent disease as second-line therapy

Stereotactic Radiosurgery (SRS) and SBRT

SRS — delivered by Gamma Knife, CyberKnife, or linear accelerator systems — is the standard treatment for brain metastases (particularly 1-4 lesions), meningiomas, acoustic neuromas, and selected recurrent GBM. Insurers deny SRS by:

• Requiring whole-brain radiation therapy (WBRT) first, even when SRS is the preferred approach for limited metastases
• Denying re-irradiation for recurrent tumors despite evidence supporting it
• Restricting SRS to specific approved centers with in-network contracts

Bevacizumab (Avastin) for Recurrent GBM

Bevacizumab is FDA-approved for recurrent GBM based on radiographic response rates. While overall survival benefit remains debated, it is the most widely used treatment for recurrent disease and is NCCN recommended. Insurers may deny it citing inconclusive overall survival benefit, despite FDA approval and NCCN listing.

VEGFR Inhibitors and Other Targeted Agents

For IDH1-mutant gliomas, ivosidenib (Tibsovo) is FDA-approved in certain settings. IDH testing (IHC and sequencing) may be denied as "investigational" despite its role as a companion diagnostic for ivosidenib approval and prognostic importance in WHO 2021 glioma classification.

Tumor Board and Second Opinion Authorizations

Patients with GBM and other high-grade brain tumors frequently require access to multidisciplinary tumor boards at academic medical centers, which may be out-of-network. Second opinion and complex case consultation may be denied as "not medically necessary" when the treating oncologist strongly recommends them.

The MGMT and IDH Testing Connection

Molecular testing of brain tumors — including MGMT promoter methylation status (predictive of temozolomide benefit), IDH1/2 mutation status, EGFR amplification, TERT promoter mutation, and 1p/19q co-deletion — is now part of the WHO 2021 integrated glioma classification and is required for proper diagnosis and treatment selection. Insurers who deny molecular testing of brain tumors are denying essential diagnostic care.

Your Legal Rights

ACA essential health benefits: Cancer treatment is covered with no annual or lifetime dollar limits.

FDA approval as documentation: Optune's FDA PMA approval is the most powerful tool against "investigational" denials. Attach the FDA approval letter and device summary to your appeal.

External Independent Review: Complete Guide" class="auto-link">External review: Independent external review with a board-certified neuro-oncologist regularly overturns Optune and SRS denials.

Expedited appeals: Brain tumor progression is rapid. Expedited 72-hour review is appropriate for time-sensitive denials.

Building Your Appeal

1. Pathology and molecular report: WHO 2021 integrated diagnosis, MGMT methylation, IDH status
2. MRI brain imaging: Baseline and post-surgical imaging confirming GBM diagnosis and residual/recurrent disease
3. NCCN Central Nervous System Tumors Guidelines: Cite specific recommendations for newly diagnosed or recurrent GBM
4. EF-14 trial publication: For Optune appeals — Stupp et al., JAMA 2015
5. FDA approval documentation for Optune: Available at FDA.gov
6. Letter of medical necessity: From board-certified neuro-oncologist, ideally at an NCI-designated cancer center
7. Optune prescribing physician documentation: Optune requires prescription by a trained physician

Fight Back With ClaimBack

ClaimBack helps brain tumor patients and families appeal insurance denials for Optune, SRS, and other critical treatments. Our platform makes it straightforward to build the evidence-based appeal your case deserves.

Start your appeal at ClaimBack

A brain tumor diagnosis demands fast access to effective treatment. Don't let an insurance denial stand between you and your care.

Related Reading

• How to Write an Insurance Appeal Letter
• What Is Medical Necessity?
• Common Reasons Insurance Claims Are Denied